Podrobný průvodce již brzy
Pracujeme na komplexním vzdělávacím průvodci pro Drug-Induced Thrombocytopenia Score. Brzy se vraťte pro podrobné vysvětlení, vzorce, příklady z praxe a odborné tipy.
Drug-Induced Thrombocytopenia (DITP) is a significant reduction in platelet count caused by medication exposure, distinct from Heparin-Induced Thrombocytopenia (HIT) which has its own dedicated scoring system. DITP accounts for approximately 25% of all cases of thrombocytopenia in hospitalised patients and is defined as a platelet count below 100 × 10^9/L (or a fall of >50% from baseline) that resolves within days to weeks of discontinuing the causative drug. Four immunological mechanisms are recognised: (1) Hapten mechanism — the drug covalently binds to a platelet membrane protein, creating a neoantigen that is recognised by drug-dependent antibodies (classic example: penicillin at high doses); (2) Immune complex mechanism — circulating drug-antibody complexes bind to platelet Fc receptors, activating complement and causing platelet destruction (classic example: quinine, quinidine); (3) Autoimmune mechanism — the drug stimulates the production of true autoantibodies against platelet glycoproteins independent of drug presence (classic example: gold salts, procainamide, some statins); (4) Direct toxicity — the drug or its metabolites directly suppress megakaryocyte production in the bone marrow (classic examples: cytotoxic chemotherapy, linezolid, valproate). The DITP diagnostic score (George and colleagues) assesses likelihood based on drug exposure timing, platelet count recovery after drug cessation, and drug re-challenge results. A platelet nadir below 50 × 10^9/L is typical of immune-mediated DITP. Quinine, vancomycin, TMP-SMX (trimethoprim-sulfamethoxazole), and heparin are among the most commonly implicated drugs, with quinine having the lowest reported threshold dose for triggering thrombocytopenia.
DITP Diagnosis: Platelet nadir typically <50 × 10^9/L; recovery within 5–7 days of drug cessation; mechanisms: hapten, immune complex, autoimmune, direct toxicity
- 1Identify temporal relationship: platelet count fell after starting the suspected drug and ideally recovers after stopping it.
- 2Review medication history for known DITP-causing drugs: quinine, quinidine, vancomycin, TMP-SMX, heparin, gold, linezolid, rifampicin, abciximab, tirofiban.
- 3Apply the DITP diagnostic criteria: definite (platelet count returns to normal after drug cessation, drug-dependent antibodies detected), probable (platelet count returns to normal but no antibody testing), possible (platelet recovers but other causes not excluded).
- 4Check platelet count trend: immune-mediated DITP typically produces a nadir <50 × 10^9/L; bone marrow suppression produces a gradual fall, not acute.
- 5Assess for bleeding: manage thrombocytopenia based on platelet count and bleeding risk (transfuse if <10 × 10^9/L with bleeding; <20 × 10^9/L before procedure).
- 6Stop the offending drug — platelet count usually recovers within 5–7 days for immune mechanisms and 7–21 days for marrow suppression.
- 7Document the drug as a cause of DITP and flag it in the allergy record to prevent re-exposure.
Quinine can cause severe thrombocytopenia from trace amounts in tonic water
The acute severe platelet fall within 48 hours of quinine exposure is classic for immune complex mechanism DITP. Even a sip of tonic water can re-trigger the reaction.
Vancomycin DITP can occur after prolonged exposure; check for concurrent HIT as well
After 10 days of vancomycin, vancomycin-dependent antibodies may develop, causing immune-mediated platelet destruction.
Dapsone alternative requires G6PD screening before use
TMP-SMX can cause DITP by immune complex and direct marrow effects. Alternative PCP prophylaxis should be used.
Abciximab causes acute DITP in ~1% of patients due to pre-existing antibodies to GPIIb/IIIa
GPIIb/IIIa inhibitors (abciximab, tirofiban, eptifibatide) can cause acute profound thrombocytopenia due to pre-existing antibodies that bind the drug-receptor complex.
Identifying the cause of unexplained thrombocytopenia in hospitalised patients by systematic medication review.. This application is commonly used by professionals who need precise quantitative analysis to support decision-making, budgeting, and strategic planning in their respective fields
Pre-prescribing risk assessment for patients being initiated on high-risk drugs (vancomycin, TMP-SMX, GPIIb/IIIa inhibitors).. Industry practitioners rely on this calculation to benchmark performance, compare alternatives, and ensure compliance with established standards and regulatory requirements
Managing platelet monitoring schedules for patients on linezolid, chemotherapy, or gold therapy.. Academic researchers and students use this computation to validate theoretical models, complete coursework assignments, and develop deeper understanding of the underlying mathematical principles
Emergency management of abciximab-associated acute profound thrombocytopenia post-coronary intervention.. Financial analysts and planners incorporate this calculation into their workflow to produce accurate forecasts, evaluate risk scenarios, and present data-driven recommendations to stakeholders
Patient education about quinine avoidance (including tonic water) after confirmed quinine-induced DITP.. This application is commonly used by professionals who need precise quantitative analysis to support decision-making, budgeting, and strategic planning in their respective fields
Quinine in Tonic Water
{'title': 'Quinine in Tonic Water', 'body': 'Quinine-induced thrombocytopenia can be triggered by as little as one glass of tonic water (containing ~83 mg quinine per litre). Patients must be warned to avoid all quinine-containing beverages, including bitter lemon drinks, as even small amounts can cause dramatic platelet falls within 24–48 hours. This is one of the most potent examples of DITP from a non-medicinal source.'}
Chemotherapy-Induced Thrombocytopenia
{'title': 'Chemotherapy-Induced Thrombocytopenia', 'body': 'Cytotoxic chemotherapy causes predictable dose-related bone marrow suppression, leading to thrombocytopenia that nadirs 10–14 days after treatment. This is a direct effect, not immune-mediated. Platelet transfusion thresholds for chemotherapy patients are well-defined: transfuse at <10 × 10^9/L (prophylactic) or <50 × 10^9/L (before invasive procedures).'} This edge case frequently arises in professional applications of dit haemolysis where boundary conditions or extreme values are involved. Practitioners should document when this situation occurs and consider whether alternative calculation methods or adjustment factors are more appropriate for their specific use case.
Linezolid Thrombocytopenia
{'title': 'Linezolid Thrombocytopenia', 'body': 'Linezolid (an oxazolidinone antibiotic used for MRSA) causes thrombocytopenia in up to 33% of patients when used for more than 14 days, primarily through mitochondrial toxicity to megakaryocytes. It is dose- and duration-dependent. Monitor platelets weekly in patients on prolonged linezolid therapy; consider switching to daptomycin or another agent if platelets fall below 100 × 10^9/L.'}
GPIIb/IIIa Inhibitor Acute Thrombocytopenia
{'title': 'GPIIb/IIIa Inhibitor Acute Thrombocytopenia', 'body': 'Abciximab, tirofiban, and eptifibatide (used during coronary interventions) can cause acute profound thrombocytopenia within hours of administration due to pre-existing naturally occurring antibodies that bind to ligand-induced binding sites (LIBS) on GPIIb/IIIa exposed by the drug. The incidence is approximately 0.5–1% and may require urgent platelet transfusion.'}
| Level | Criteria | Action |
|---|---|---|
| Definite | Platelet count normalises after stopping drug AND drug-dependent antibodies detected | Document in allergy record; no re-exposure |
| Probable | Platelet count normalises after stopping drug; no antibody testing | Treat as definite; flag drug |
| Possible | Platelet count improves but other causes not excluded | Consider further testing; caution with re-exposure |
| Unlikely | Platelet count does not recover after stopping drug | Search for alternative causes |
How quickly does the platelet count recover after stopping the drug in DITP?
For immune-mediated DITP (hapten, immune complex, autoimmune mechanisms), the platelet count typically begins recovering within 2–3 days and returns to normal within 5–7 days after drug cessation. For marrow suppression (e.g., cytotoxic chemotherapy, linezolid, valproate), recovery takes longer — typically 7–21 days — as new megakaryocytes must be produced. The process involves applying the underlying formula systematically to the given inputs.
How is DITP differentiated from ITP (immune thrombocytopenic purpura)?
The key distinction is temporal relationship to drug exposure and recovery on drug cessation. ITP has no identifiable drug trigger and does not resolve when drugs are stopped. Drug-dependent antibody testing (where available) can confirm DITP. In practice, if a patient has unexplained thrombocytopenia, a careful medication review looking for timing of platelet fall relative to drug initiation is essential.
Which drugs most commonly cause DITP?
The most commonly implicated drugs include quinine and quinidine (tonic water, antimalarial use), vancomycin, trimethoprim-sulfamethoxazole (TMP-SMX), rifampicin, heparin (which has its own dedicated scoring system — HIT), gold salts, abciximab and other GPIIb/IIIa inhibitors, and cytotoxic chemotherapy agents. The DITP database (George et al.) catalogues over 300 reported drug causes.
Should platelets be transfused in DITP?
Platelet transfusion is generally indicated only for active clinically significant bleeding or before high-risk procedures when platelets are below 50 × 10^9/L. Prophylactic platelet transfusion (without bleeding) is considered when platelets fall below 10–20 × 10^9/L. In immune-mediated DITP, transfused platelets are rapidly destroyed by the same antibody mechanism, limiting their benefit.
Can a patient re-take the causative drug after DITP recovery?
Drug re-challenge should be avoided if the drug is not essential. In immune complex DITP (e.g., quinine), re-exposure — even to trace amounts — can cause relapse within hours to minutes, sometimes more severe than the original episode. If re-challenge is unavoidable for clinical reasons, it must be performed in a monitored setting with platelet count checked within 24–48 hours.
What is the difference between DITP and HIT?
HIT (Heparin-Induced Thrombocytopenia) is a specific, immunologically distinct form of DITP caused by heparin-dependent antibodies against platelet factor 4 (PF4) complexes. Unlike most DITP where thrombocytopenia causes bleeding risk, HIT paradoxically increases thrombosis risk (both venous and arterial). HIT is scored separately using the 4T Score, requires heparin to be stopped immediately, and mandates non-heparin anticoagulation.
How do I test for drug-dependent antibodies?
Drug-dependent antibody testing is performed by specialised reference laboratories. The test involves incubating patient serum with normal donor platelets in the presence of the suspect drug — if the patient's antibodies bind platelets only in the drug's presence (detected by flow cytometry or ELISA), this confirms drug-dependent antibody and supports the DITP diagnosis. This testing is not widely available and results may take days to weeks.
What happens if the causative drug is not identified and stopped?
Failure to identify and stop the causative drug leads to persistent thrombocytopenia, ongoing risk of serious bleeding, and unnecessary immunosuppressive treatment for presumed ITP. In severe cases (platelet count <5 × 10^9/L), intracranial haemorrhage can occur. A systematic review of all medications — including over-the-counter drugs, herbal supplements, and even beverages such as tonic water — is critical.
Pro Tip
When investigating unexplained thrombocytopenia in a hospitalised patient, create a timeline: list every drug and its start date alongside the date the platelet count began to fall. The drug started 1–21 days before the platelet nadir is the prime suspect. The DITP database at www.ouhsc.edu/platelets provides a searchable list of implicated drugs.
Did you know?
Quinine was the very first drug identified to cause immune-mediated thrombocytopenia. The association was first reported by William Vipan in 1865 when he described a patient who developed purpura every time they took quinine for malaria. This was one of the earliest documented examples of a drug adverse effect being linked to a specific medication — nearly 80 years before the term 'immune-mediated' would be understood.
References
- ›George JN et al — Drug-Induced Thrombocytopenia (NEJM 1998)
- ›DITP Drug Database — University of Oklahoma
- ›Arnold DM et al — DITP: A Structured Review (Blood 2013)
- ›BSH Guidelines on Investigation and Management of Thrombocytopenia
- ›Warkentin TE — Drug-Induced Immune-Mediated Thrombocytopenia (Hematol Oncol Clin NA)